NuVasive (NSDQ:NUVA) is paying dearly for a $101 million judgment against it in a patent war with Medtronic (NYSE:MDT), as Wall Street investors pare nearly 14 percent from its share price today after the release of its third-quarter earnings.
Investors pounded NuVasive Inc. today, sending share prices down nearly 14 percent as of about noon, after the spine surgery company released its Wall-Street-beating third-quarter results.
San Diego-based NuVasive posted a net loss of $67.6 million, or $1.69 per share, on sales of $132.9 million – a top-line gain of 10.5 percent but a far cry earnings-wise from the $8.5 million reported during the same period last year.
The net loss was largely due to a $103.7 million charge for "certain intellectual property litigation expenses," according to a press release.
That would be a federal jury award of $101.2 million to Medtronic after the panel found last month that NuVasive infringed patents covering spinal implant technology. Excluding such one-time items, NuVasive posted adjusted EPS of 26 cents, beating The Street’s expectation of 23 cents.
"Our financial performance in the third quarter of 2011 attests to exceptional execution by the NuVasive team. In the face of an extremely challenging spine market, we delivered industry leading growth and executed a strategic transaction that will enhance the penetration of XLIF and NeuroVision for years to come," chairman & CEO Alex Lukianov said in prepared remarks. "[W]e will continue to remain laser-focused on pushing toward our next milestone of being a $1 billion company, with increasing profitability, to serve the needs of spine surgery patients."
NuVasive boosted its full-year sales guidance to between $538 million and $540 million, up from $530 million to $540 million, but cut its earnings forecast to reflect expected losses of $1.43 to $1.42 per share. The company had expected EPS 33 cents to 36 cents.
NUVA shares were trading at $15.35 as of about 12:15, down 13.7 percent for the day.
MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Varian’s FY2011 sales, earnings rise at a double-digit clip
Sales and profits for Varian Medical Systems (NYSE:VAR) rose at a double-digit clip during fiscal 2011, growing 19.6 percent and 10.7 percent, respectively
The Palo Alto-based radiosurgery device maker reported profits of $398.9 million, or $3.36 per share, on sales of $2.93 billion for the 12 months ended Sept. 30. That compares with profits of $3603.4 million, or $2.91 per share, on sales of $2.49 billion during FY2010.
For the fourth quarter, Varian posted income of $100.7 million (87 cents EPS), down 4.1 percent, on sales of $719.0 million – a 10.3 percent top-line increase. That compares with profits of $105.0 million, or 87 cents EPS, during Q$ 2010. Read more
Orthofix nearly doubles Q3 profits, shares rise 9%
Orthofix International (NSDQ:OFIX) nearly doubled its third-quarter profits, sending its share price up nearly 9 percent today on Wall Street.
The orthopedic device maker reported profits of 12.4 million, or 66 cents per share, on sales of $144.7 million for the three months ended Sept. 30. That compares with profits of $8.5 million, or 48 cents per share, on sales of $138.9 million, for top-line growth of 24.2 percent. Read more
That compares with profits of $60.9 million, or 36 cents per share, on sales of $462.7 million during the same period last year.
That’s a bottom-line increase of 29.5 percent and top-line growth of 23.5 percent. Read more
The Italian cardiac device maker reported profits of about $17.1 million (€12.1 million) on sales of $242.8 million (€171.4 million) for the period.
That compares with profits of $11.6 million (€8.2 million) on sales of $255.4 million (€180.3 million) during Q3 2010. Read more
Shire reported overall profits of $192.9 million, or $1.02 per share, on sales of $1.09 billion for the three months ended Sept. 30.
That’s almost double the bottom line from Q3 2010, when Shire logged profits of $96.3 million, or 52 cents per share, on sales of $874.3 million. Read more